Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study

被引:15
作者
Pathadka, Swathi [1 ]
Yan, Vincent K. C. [1 ]
Li, Xue [1 ,2 ,3 ]
Tse, Gary [4 ]
Wan, Eric Y. F. [1 ,5 ]
Lau, Hayden [1 ,6 ]
Lau, Wallis C. Y. [1 ,7 ]
Siu, David C. W. [8 ]
Chan, Esther W. [1 ]
Wong, Ian C. K. [1 ,7 ]
机构
[1] Univ Hong Kong, Dept Pharmacol & Pharm, Li Ka Shing Fac Med, Ctr Safe Medicat Practice & Res, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China
[3] Univ Hong Kong, Fac Social Sci, Dept Social Work & Social Adm, Hong Kong, Peoples R China
[4] Xiamen Univ, Xiamen Cardiovasc Hosp, Xiamen, Peoples R China
[5] Univ Hong Kong, Li Ka Shing Fac Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[6] Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Accid & Emergency, Hong Kong, Peoples R China
[7] UCL, Sch Pharm, Res Dept Practice & Policy, London, England
[8] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2021年 / 7卷
关键词
heart failure; sacubitril; valsartan; enalapril; pharmacoepidemiolgy; mortality; hospitalization; VALSARTAN; LCZ696; DABIGATRAN; OUTCOMES; DEATH; ASIA;
D O I
10.3389/fcvm.2020.602363
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45-0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45-0.77), all-cause mortality (HR 0.51; 95% CI, 0.36-0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70-1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39-1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age >= 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population.
引用
收藏
页数:8
相关论文
共 32 条
  • [1] Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure
    Albert, Nancy M.
    Swindle, Jason P.
    Buysman, Erin K.
    Chang, Chunlan
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (09):
  • [2] An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction
    Antol, Dana Drzayich
    Casebeer, Adrianne Waldman
    DeClue, Richard W.
    Stemkowski, Stephen
    Russo, Patricia A.
    [J]. ADVANCES IN THERAPY, 2018, 35 (06) : 785 - 795
  • [3] Patient Characteristics From a Regional Multicenter Database of Acute Decompensated Heart Failure in Asia Pacific (ADHERE International-Asia Pacific)
    Atherton, John J.
    Hayward, Christopher S.
    Ahmad, Wan Azman Wan
    Kwok, Bernard
    Jorge, Jesus
    Hernandez, Adrian F.
    Liang, Li
    Kociol, Robb D.
    Krum, Henry
    [J]. JOURNAL OF CARDIAC FAILURE, 2012, 18 (01) : 82 - 88
  • [4] Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study
    Chan, Esther W.
    Lau, Wallis C. Y.
    Leung, Wai K.
    Mok, Michael T. C.
    He, Ying
    Tong, Teresa S. M.
    Wong, Ian C. K.
    [J]. GASTROENTEROLOGY, 2015, 149 (03) : 586 - +
  • [5] Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation
    Chang, Hung-Yu
    Feng, An-Ning
    Fong, Man-Cai
    Hsueh, Chao-Wen
    Lai, Wei-Tsung
    Huang, Kuan-Chih
    Chong, Eric
    Chen, Chi-Nan
    Chang, Hung-Chuan
    Yin, Wei-Hsian
    [J]. JOURNAL OF CARDIOLOGY, 2019, 74 (3-4) : 372 - 380
  • [6] Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases
    Curtis, Lesley H.
    Hammill, Bradley G.
    Eisenstein, Eric L.
    Kramer, Judith M.
    Anstrom, Kevin J.
    [J]. MEDICAL CARE, 2007, 45 (10) : S103 - S107
  • [7] Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
    Desai, Akshay S.
    Claggett, Brian L.
    Packer, Milton
    Zile, Michael R.
    Rouleau, Jean L.
    Swedberg, Karl
    Shi, Victor
    Lefkowitz, Martin
    Starling, Randall
    Teerlink, John
    McMurray, John J. V.
    Solomon, Scott D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (03) : 242 - 248
  • [8] Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
    Desai, Akshay S.
    McMurray, John J. V.
    Packer, Milton
    Swedberg, Karl
    Rouleau, Jean L.
    Chen, Fabian
    Gong, Jianjian
    Rizkala, Adel R.
    Brahimi, Abdel
    Claggett, Brian
    Finn, Peter V.
    Hartley, Loren Howard
    Liu, Jiankang
    Lefkowitz, Martin
    Shi, Victor
    Zile, Michael R.
    Solomon, Scott D.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (30) : 1990 - 1997
  • [9] Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States
    DeVore, Adam D.
    Hill, C. Larry
    Thomas, Laine
    Sharma, Puza P.
    Albert, Nancy M.
    Butler, Javed
    Patterson, J. Herbert
    Spertus, John A.
    Williams, Fredonia B.
    Duffy, Carol I.
    McCague, Kevin
    Hernandez, Adrian F.
    Fonarow, Gregg C.
    [J]. CIRCULATION-HEART FAILURE, 2018, 11 (09) : e005400
  • [10] Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas
    Dewan, Pooja
    Jhund, Pardeep S.
    Shen, Li
    Petrie, Mark C.
    Abraham, William T.
    Ali, M. Atif
    Chen, Chen-Huan
    Desai, Akshay S.
    Dickstein, Kenneth
    Huang, Jun
    Kiatchoosakun, Songsak
    Kim, Kee-Sik
    Kober, Lars
    Lai, Wen-Ter
    Liao, Yuhua
    Mogensen, Ulrik M.
    Oh, Byung-Hee
    Packer, Milton
    Rouleau, Jean L.
    Shi, Victor
    Sibulo, Antonio S., Jr.
    Solomon, Scott D.
    Sritara, Piyamitr
    Swedberg, Karl
    Tsutsui, Hiroyuki
    Zile, Michael R.
    McMurray, John J., V
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (05) : 577 - 587